Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
palmitoylethanolamide + cannabinoids
- Development stage
- Preclinical
- Lead developer
- SciSparc
- Modality
- Small Molecules
- Administration
- Oral, Intraperitoneal, Subcutaneous, Intravenous, Intrathecal, Intraplantar, Topical, Ophthalmic, Inhalation, Intranasal, Transdermal, Sublingual, Rectal
01
Overview
Palmitoylethanolamide (PEA) + cannabinoids is a combination therapeutic candidate being developed by APIRx Pharma Sciences. The formulation utilizes a proprietary microencapsulation delivery technology to combine PEA, an endogenous fatty acid amide, with cannabinoids for the treatment of pain and inflammatory conditions. PEA acts as an agonist of the peroxisome proliferator-activated receptor alpha (PPAR-alpha), which modulates the expression of genes involved in pain and inflammation. Furthermore, PEA is known to exert an "entourage effect" by enhancing the activity of endocannabinoids through the inhibition of their degradation. By combining PEA with exogenous cannabinoids, the therapy aims to achieve synergistic efficacy through the dual modulation of the endocannabinoid system and PPAR-alpha signaling pathways.
- Other names
- palmitoylethanolamide (PEA) + cannabinoid microencapsulation
02
Targets
CNR1 (Cannabinoid receptor 1)TRPV1 (Transient receptor potential cation channel subfamily V member 1)PPARA (Peroxisome proliferator-activated receptor alpha)FAAH
Beyond the preview
Go deeper on palmitoylethanolamide + cannabinoids.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on palmitoylethanolamide + cannabinoids.